Prof Marie-Liesse Asselin-Labat
Honorary (Professorial Fellow)
Department of Medical Biology (WEHI)
107 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Epigenetic Imprinting Bridges Infection and Lung Cancer
DOI: 10.1158/0008-5472.CAN-26-15112026
Journal article
TNF-⍺-mediated myeloid-instructed CD14 CD4 T cells are associated with poor survival in lung adenocarcinoma
DOI: 10.1016/j.xcrm.2026.1025932026
Journal article
In Vivo 4D X-Ray Dark-Field Lung Imaging in Mice
DOI: 10.1109/TMI.2025.35956662025
Journal article
Non-apoptotic caspase-8 is critical for orchestrating exaggerated inflammation during severe SARS-CoV-2 infection
DOI: 10.1038/s41467-025-65098-z2025
Journal article
Mapping lung cancer ventilation dynamics using functional imaging and lung mechanics
DOI: 10.1242/dmm.0525592025
Journal article
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.CCR-25-14492025
Other
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618195
RECENT SCHOLARLY WORKS
2025
Other
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182012025
Other
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182042025
Other
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618189
RECENT PROJECTS
2011
Research Grant
Lung Stem and Progenitor Cell Markers as Prognostic and Therapeutic Targets in Lung Cancer